EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Priscilla A Hollander iD, Heidi Krause-Steinrauf iD, Nicole M Butera, Erin J Kazemi, Andrew J Ahmann iD, Basma N Fattaleh, Mary L Johnson, Tina Killean, Violet S Lagari, Mary E Larkin, Elizabeth A Legowski, Neda Rasouli iD und 3 weitere

Diabetes Care · 2024

DOI: 10.2337/dc23-0516 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Priscilla A Hollander und 14 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott & White Research Institute, Dallas, TX. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Sulfonylurea Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To describe rescue insulin use and associated factors in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS GRADE participants (type 2 diabetes duration <10 years, baseline A1C 6.8%–8.5% on metformin monotherapy, N = 5,047) were randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin and followed quarterly for a mean of 5 years. Rescue insulin (glargine or aspart) was to be started within 6 weeks of A1C >7.5%, confirmed. Reasons for delaying rescue insulin were reported by staff-completed survey. RESULTS Nearly one-half of GRADE participants (N = 2,387 [47.3%]) met the threshold for rescue insulin. Among participants assigned to glimepiride, liraglutide, or sitagliptin, rescue glargine was added by 69% (39% within 6 weeks). Rescue aspart was added by 44% of glargine-assigned participants (19% within 6 weeks) and by 30% of non-glargine-assigned participants (14% within 6 weeks). Higher A1C values were associated with adding rescue insulin. Intention to change health behaviors (diet/lifestyle, adherence to current treatment) and not wanting to take insulin were among the most common reasons reported for not adding rescue insulin within 6 weeks. CONCLUSIONS Proportionately, rescue glargine, when required, was more often used than rescue aspart, and higher A1C values were associated with greater rescue insulin use. Wanting to use noninsulin strategies to improve glycemia was commonly reported, although multiple factors likely contributed to not using rescue insulin. These findings highlight the persistent challenge of intensifying type 2 diabetes treatment with insulin, even in a clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminSulfonylurea CompoundsHumansInsulinInsulin GlargineHypoglycemic AgentsLiraglutideGlycated HemoglobinBlood GlucoseSitagliptin PhosphateInsulin, Regular, Human

Substanzen

InsulinglimepirideInsulin GlargineHypoglycemic AgentsLiraglutideGlycated HemoglobinBlood GlucoseMetforminSitagliptin PhosphateInsulin, Regular, Human

Autor:innen und Institutionen

  • Baylor Scott & White Research Institute, Dallas, TX.
  • The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
  • Oregon Health & Science University, Portland, OR.
  • VA Puget Sound Health Care System, Seattle, WA.
  • International Diabetes Center at Park Nicollet, Minneapolis, MN.
  • Southwestern American Indian Center, Phoenix, AZ.

ORCID-Profile: Priscilla A Hollander, Heidi Krause-Steinrauf, Andrew J Ahmann, Neda Rasouli

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • CDC HHS
  • American Diabetes Association
  • Centers for Disease Control and Prevention
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Hollander, P. A., Krause-Steinrauf, H., Butera, N. M., Kazemi, E. J., Ahmann, A. J., Fattaleh, B. N., Johnson, M. L., Killean, T., Lagari, V. S., Larkin, M. E., Legowski, E. A., Rasouli, N., Willis, H. J., Martin, C. L., & GRADE Research Group (2024). The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. https://doi.org/10.2337/dc23-0516

Vancouver

Hollander PA, Krause-Steinrauf H, Butera NM, Kazemi EJ, Ahmann AJ, Fattaleh BN, et al. The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. doi:10.2337/dc23-0516

BibTeX
@article{Hollander2024,
  author = {Hollander, Priscilla A and Krause-Steinrauf, Heidi and Butera, Nicole M and Kazemi, Erin J and Ahmann, Andrew J and Fattaleh, Basma N and Johnson, Mary L and Killean, Tina and Lagari, Violet S and Larkin, Mary E and Legowski, Elizabeth A and Rasouli, Neda and Willis, Holly J and Martin, Catherine L and GRADE Research Group, GRADE Research Group},
  title = {The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-0516}
}
Kostenlos starten →